FORM Wealth Advisors LLC Acquires Shares of 7,896 Exact Sciences Corporation (NASDAQ:EXAS)

FORM Wealth Advisors LLC bought a new stake in Exact Sciences Corporation (NASDAQ:EXAS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,896 shares of the medical research company's stock, valued at approximately $342,000.

Other large investors also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Exact Sciences in the fourth quarter valued at approximately $45,000. AlphaQuest LLC lifted its holdings in shares of Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after purchasing an additional 913 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in Exact Sciences during the fourth quarter worth $66,000. Ostrum Asset Management lifted its holdings in Exact Sciences by 28.4% during the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock worth $134,000 after acquiring an additional 527 shares during the period. Finally, Raiffeisen Bank International AG bought a new stake in Exact Sciences during the fourth quarter worth $149,000. Institutional investors own 88.82% of the company's stock.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $52.54 on Tuesday. The stock has a market cap of $9.91 billion, a PE ratio of -9.54, a price-to-earnings-growth ratio of 40.25 and a beta of 0.98. Exact Sciences Corporation has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.38 and a current ratio of 2.73. The stock has a fifty day moving average of $52.04 and a 200-day moving average of $51.64.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. The business had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. During the same period in the previous year, the business earned ($0.60) earnings per share. The firm's revenue was up 10.9% on a year-over-year basis. Equities research analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Insiders Place Their Bets

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of Exact Sciences stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $53.20, for a total transaction of $170,612.40. Following the completion of the sale, the director now owns 72,759 shares of the company's stock, valued at $3,870,778.80. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on EXAS shares. Robert W. Baird lifted their price target on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Piper Sandler dropped their price target on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Scotiabank lifted their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Royal Bank Of Canada lifted their price target on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. Finally, Barclays lifted their price target on Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.